Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Ropinirole (02326590), Jamp-Ropinirole (02352338), PMS-Ropinirole (02326612), Jamp-Ropinirole (02352346), PMS-Ropinirole (02326620), Jamp-Ropinirole (02352354). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

ROPINIROLE

8 general benefit · 4 not a benefit

Other products in the same Health Canada class (N04B, N04BC) — coverage varies; not interchangeable

  • Bromocriptine (Parlodel): general benefit, Not a benefit
  • Amantadine (Symmetrel): general benefit, Not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, Limited Use, Not a benefit
  • Selegiline (Eldepryl): general benefit, Not a benefit
  • Carbidopa + entacapone + levodopa (Stalevo): limited Use 367

Ran-Ropinirole · DIN 02314037 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ropinirole · DIN 02314037 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2009-09-30 Health Canada: Marketed since 2025-06-26 · brand SPC-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 0.25 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ropinirole: Formulary list price $0.1441/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1441 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79955 · Verify on the e-Formulary ↗ (DIN 02314037)

Source record
DIN 02314037: Ran-Ropinirole Raw flags: sec3=Y Item: 920000289; group id 953; item number 2263; lccId None; manufacturer id RAN Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1441; ministry $0.1441 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02314037 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79955
Interchangeable products
ReQuip · DIN 02232565 · not recorded Teva-Ropinirole · DIN 02316846 · $0.1441
Shortage status: resolved shortage (ended 2026-04-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02314037
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Ropinirole · DIN 02316846 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ropinirole · DIN 02316846 Manufacturer: Teva Canada Limited; listing date 2009-09-30 Health Canada: Marketed since 2020-05-22 · brand TEVA-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 0.25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ropinirole: Formulary list price $0.1441/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1441 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80234 · Verify on the e-Formulary ↗ (DIN 02316846)

Source record
DIN 02316846: Teva-Ropinirole Raw flags: sec3=Y Item: 920000289; group id 953; item number 2263; lccId None; manufacturer id TEV Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.1441; ministry $0.1441 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316846 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80234
Interchangeable products
Ran-Ropinirole · DIN 02314037 · $0.1441 ReQuip · DIN 02232565 · not recorded
Shortage status: resolved shortage (ended 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316846
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ropinirole · DIN 02314053 · 1mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ropinirole · DIN 02314053 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2009-09-30 Health Canada: Marketed since 2025-06-26 · brand SPC-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 1 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ropinirole: Formulary list price $0.5762/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5762 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79957 · Verify on the e-Formulary ↗ (DIN 02314053)

Source record
DIN 02314053: Ran-Ropinirole Raw flags: sec3=Y Item: 920000290; group id 953; item number 2264; lccId None; manufacturer id RAN Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.5762; ministry $0.5762 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02314053 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79957
Interchangeable products
ReQuip · DIN 02232567 · not recorded Teva-Ropinirole · DIN 02316854 · $0.5762
Shortage status: resolved shortage (ended 2024-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02314053
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Ropinirole · DIN 02316854 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ropinirole · DIN 02316854 Manufacturer: Teva Canada Limited; listing date 2009-09-30 Health Canada: Marketed since 2020-05-22 · brand TEVA-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 1 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ropinirole: Formulary list price $0.5762/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5762 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80235 · Verify on the e-Formulary ↗ (DIN 02316854)

Source record
DIN 02316854: Teva-Ropinirole Raw flags: sec3=Y Item: 920000290; group id 953; item number 2264; lccId None; manufacturer id TEV Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.5762; ministry $0.5762 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316854 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80235
Interchangeable products
Ran-Ropinirole · DIN 02314053 · $0.5762 ReQuip · DIN 02232567 · not recorded
Shortage status: resolved shortage (ended 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316854
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ropinirole · DIN 02314061 · 2mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ropinirole · DIN 02314061 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2009-09-30 Health Canada: Marketed since 2025-06-26 · brand SPC-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ropinirole: Formulary list price $0.6338/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6338 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79958 · Verify on the e-Formulary ↗ (DIN 02314061)

Source record
DIN 02314061: Ran-Ropinirole Raw flags: sec3=Y Item: 920000291; group id 953; item number 2265; lccId None; manufacturer id RAN Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.6338; ministry $0.6338 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02314061 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79958
Interchangeable products
ReQuip · DIN 02232568 · not recorded Teva-Ropinirole · DIN 02316862 · $0.6338
Shortage status: resolved shortage (ended 2023-11-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02314061
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Ropinirole · DIN 02316862 · 2mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ropinirole · DIN 02316862 Manufacturer: Teva Canada Limited; listing date 2009-09-30 Health Canada: Marketed since 2020-05-22 · brand TEVA-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ropinirole: Formulary list price $0.6338/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6338 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80236 · Verify on the e-Formulary ↗ (DIN 02316862)

Source record
DIN 02316862: Teva-Ropinirole Raw flags: sec3=Y Item: 920000291; group id 953; item number 2265; lccId None; manufacturer id TEV Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.6338; ministry $0.6338 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316862 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80236
Interchangeable products
Ran-Ropinirole · DIN 02314061 · $0.6338 ReQuip · DIN 02232568 · not recorded
Shortage status: resolved shortage (ended 2025-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316862
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ropinirole · DIN 02314088 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ropinirole · DIN 02314088 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2009-09-30 Health Canada: Marketed since 2025-06-26 · brand SPC-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 5 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ropinirole: Formulary list price $1.7450/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79959 · Verify on the e-Formulary ↗ (DIN 02314088)

Source record
DIN 02314088: Ran-Ropinirole Raw flags: sec3=Y Item: 920000292; group id 953; item number 2266; lccId None; manufacturer id RAN Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $1.7450; ministry $1.7450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02314088 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79959
Interchangeable products
ReQuip · DIN 02232569 · not recorded Teva-Ropinirole · DIN 02316870 · $1.7450
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02314088
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Ropinirole · DIN 02316870 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ropinirole · DIN 02316870 Manufacturer: Teva Canada Limited; listing date 2009-09-30 Health Canada: Marketed since 2020-05-22 · brand TEVA-ROPINIROLE · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ropinirole: Formulary list price $1.7450/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80237 · Verify on the e-Formulary ↗ (DIN 02316870)

Source record
DIN 02316870: Teva-Ropinirole Raw flags: sec3=Y Item: 920000292; group id 953; item number 2266; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $1.7450; ministry $1.7450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80237
Interchangeable products
Ran-Ropinirole · DIN 02314088 · $1.7450 ReQuip · DIN 02232569 · not recorded
Shortage status: resolved shortage (ended 2025-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316870
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ReQuip · DIN 02232565 · 0.25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-10-31 — choose a marketed DIN from the same-category list.Discontinued 2017-10-31 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-10-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
ReQuip · DIN 02232565 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-04-17 Health Canada: Cancelled post market since 2017-10-31 · brand REQUIP · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 0.25 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

ReQuip: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52041 · Verify on the e-Formulary ↗ (DIN 02232565)

Source record
DIN 02232565: ReQuip Raw flags: notABenefit=Y, sec3=Y Item: 920000289; group id 953; item number 2263; lccId None; manufacturer id GSK Source form: Tab; strength: 0.25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232565 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52041
Interchangeable products
Ran-Ropinirole · DIN 02314037 · $0.1441 Teva-Ropinirole · DIN 02316846 · $0.1441
Shortage status: discontinued (2017-10-31, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232565
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-10-31 — choose a marketed DIN from the same-category list.

ReQuip · DIN 02232567 · 1mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-05 — choose a marketed DIN from the same-category list.Discontinued 2018-03-05 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-03-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
ReQuip · DIN 02232567 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-04-17 Health Canada: Cancelled post market since 2018-03-05 · brand REQUIP · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 1 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

ReQuip: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52043 · Verify on the e-Formulary ↗ (DIN 02232567)

Source record
DIN 02232567: ReQuip Raw flags: notABenefit=Y, sec3=Y Item: 920000290; group id 953; item number 2264; lccId None; manufacturer id GSK Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232567 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52043
Interchangeable products
Ran-Ropinirole · DIN 02314053 · $0.5762 Teva-Ropinirole · DIN 02316854 · $0.5762
Shortage status: discontinued (2018-03-05, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232567
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-03-05 — choose a marketed DIN from the same-category list.

ReQuip · DIN 02232568 · 2mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.Discontinued 2018-03-02 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
ReQuip · DIN 02232568 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-04-17 Health Canada: Cancelled post market since 2018-03-02 · brand REQUIP · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

ReQuip: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52044 · Verify on the e-Formulary ↗ (DIN 02232568)

Source record
DIN 02232568: ReQuip Raw flags: notABenefit=Y, sec3=Y Item: 920000291; group id 953; item number 2265; lccId None; manufacturer id GSK Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232568 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52044
Interchangeable products
Ran-Ropinirole · DIN 02314061 · $0.6338 Teva-Ropinirole · DIN 02316862 · $0.6338
Shortage status: discontinued (2018-03-02, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232568
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.

ReQuip · DIN 02232569 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-01 — choose a marketed DIN from the same-category list.Discontinued 2018-03-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-03-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
ReQuip · DIN 02232569 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-04-17 Health Canada: Cancelled post market since 2018-03-01 · brand REQUIP · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 5 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

ReQuip: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52047 · Verify on the e-Formulary ↗ (DIN 02232569)

Source record
DIN 02232569: ReQuip Raw flags: notABenefit=Y, sec3=Y Item: 920000292; group id 953; item number 2266; lccId None; manufacturer id GSK Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232569 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52047
Interchangeable products
Ran-Ropinirole · DIN 02314088 · $1.7450 Teva-Ropinirole · DIN 02316870 · $1.7450
Shortage status: discontinued (2018-03-01, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232569
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-03-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults: SPC-ROPINIROLE (Ropinirole Tablets) is indicated in the treatment of the signs and symptoms of idiopathic Parkinson's disease. SPC-ROPINIROLE can be used both as early therapy without concomitant levodopa and as an adjunct to levodopa. Geriatrics (> 65 years of age): Oral clearance of SPC-ROPINIROLE is reduced in patients older than 65 years of age, however the dosing of ropinirole for elderly patients can be titrated in the normal manner. (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics). Paediatrics (≤ 18 years of age): The safety and efficacy of Ropinirole Tablets have not been established in children under 18 years of age, therefore SPC-ROPINIROLE is not recommended in this patient population. https://pdf.hres.ca/dpd_pm/00081006.PDF PM date: JUN 26, 2025 Source product: SPC-ROPINIROLE; DIN 02314037; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ran-Ropinirole · DIN 02314088 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02314088

Check this DIN again

ReQuip · DIN 02232565 Shortage status: discontinued (2017-10-31, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232565

Check this DIN again

ReQuip · DIN 02232567 Shortage status: discontinued (2018-03-05, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232567

Check this DIN again

ReQuip · DIN 02232568 Shortage status: discontinued (2018-03-02, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232568

Check this DIN again

ReQuip · DIN 02232569 Shortage status: discontinued (2018-03-01, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232569

Check this DIN again

Other review policies

For ReQuip: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026